आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - raloxifene hydrochloride - film coated tablet - 60 milligram - raloxifene

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

physicians total care, inc. - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

eli lilly and company - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-y

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

teva b.v. - raloxifene hydrochloride - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. a significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.when determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - raloxifene hydrochloride -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - raloxifene hydrochloride -

यूनाइटेड किंगडम - अंग्रेज़ी - myHealthbox

fair-med healthcare gmbh - raloxifene hydrochloride - film-coated tablets - 60mg - selective oestrogen receptor modulator - it is indicated for the treatment and prevention of osteoporosis in postmenopausal women. a significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.

इसराइल - अंग्रेज़ी - Ministry of Health

teva israel ltd - raloxifene hydrochloride - tablets - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women.- prevention of osteoporosis in post menopausal women.- reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. - reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

इसराइल - अंग्रेज़ी - Ministry of Health

teva israel ltd - raloxifene hydrochloride - tablets - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women.- prevention of osteoporosis in post menopausal women.- reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. - reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

माल्टा - अंग्रेज़ी - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - raloxifene hydrochloride - film-coated tablet - raloxifene hydrochloride 60 mg - sex hormones and modulators of the genital system